Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, Solodovnikova V, Viatushka D, Parpieva N, Safaev K, Liverko I, Tigay Z, Moe S, Khristusev A, Allamuratova S, Mirzabaev S, Achilov M, Samieva N, Lachenal N, Merle CS, Sall FB, Restrepo CG, Tan C, Sitali N, Saunders MJ. Sinha A, et al. Among authors: liverko i. Clin Infect Dis. 2025 Nov 6;81(4):838-845. doi: 10.1093/cid/ciaf035. Clin Infect Dis. 2025. PMID: 39964841 Free PMC article.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: liverko i. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Among authors: liverko i. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, Liverko I, Usmanova R, Butabekov I, Moodliar R, Mbenga M, Rasool M, Nyang'wa BT, Berry C. Crocker-Buque T, et al. Among authors: liverko i. Clin Infect Dis. 2024 Aug 16;79(2):569-570. doi: 10.1093/cid/ciad767. Clin Infect Dis. 2024. PMID: 38419566 Free PMC article. No abstract available.
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C. Motta I, et al. Among authors: liverko i. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0053624. doi: 10.1128/aac.00536-24. Epub 2024 Jun 6. Antimicrob Agents Chemother. 2024. PMID: 38842323 Free PMC article. Clinical Trial.
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort.
Jansen van Vuuren J, Crocker-Buque T, Berry C, Viatushka D, Usmanova R, Nyang'wa BT, Parpieva N, Liverko I, Solodovnikova V, Sinha A. Jansen van Vuuren J, et al. Among authors: liverko i. PLOS Glob Public Health. 2024 Sep 24;4(9):e0003057. doi: 10.1371/journal.pgph.0003057. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39316626 Free PMC article.
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation.
Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso GM, Jolivet P, Abdrasuliev T, Moe S, Aw PS, Samieva N, Nyang'wa BT. Sweeney S, et al. Among authors: liverko i. Lancet Glob Health. 2025 Feb;13(2):e355-e363. doi: 10.1016/S2214-109X(24)00467-4. Lancet Glob Health. 2025. PMID: 39890235 Free article.
Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study.
Lowton K, Stringer B, Cusinato M, Fielding K, Liverko I, Moodliar R, Nikolaevna TZ, Solodovnikova V, Kazounis E, Nyang'wa BT. Lowton K, et al. Among authors: liverko i. IJTLD Open. 2026 May 11;3(5):319-326. doi: 10.5588/ijtldopen.25.0823. eCollection 2026 May. IJTLD Open. 2026. PMID: 42125015 Free PMC article.
19 results